BIOMAT Database Logo BIOMAT Database Logo

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. 2000

P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
Center for Clinical and Basic Research, Ballerup, Denmark.

We studied the effect on bone mass of alendronate treatment for 5 yr and its withdrawal. Four hundred and forty-seven postmenopausal women with normal bone mass entered a 3-yr randomized trial followed by a 2-yr open label extension. Three hundred and eleven women completed the first 3 yr, and 263 consented to continue and completed the extension. We are reporting data from groups using the dose of alendronate currently approved for osteoporosis prevention (5 mg) or from the group in which alendronate treatment was withdrawn: 52 women received alendronate (5 mg) for 5 yr (group I), 56 received 3 yr of placebo followed by alendronate (5 mg) for 2 yr (group II), and 52 received alendronate (20 mg) for 2 yr followed by 3 yr off therapy (group III). In group I, alendronate (5 mg) increased bone mineral density (BMD) at the spine and trochanter by 2.5-3.2% (P < 0.001 vs. baseline) and stabilized total body and femoral neck BMD (change vs. baseline, P = NS) over 5 yr. By the end of 5 yr, BMD was comparable at the spine, hip, and total body in groups I and III. The 3-yr decrease in BMD after withdrawal of alendronate (20 mg) in group III was 1.8-5.7% (P < 0.01 vs. baseline) and similar to the 3-yr decrease in BMD in group II during the initial 3 yr. In conclusion, alendronate (5 mg) for 5 yr or alendronate (20 mg) for 2 yr followed by 3 yr off therapy prevented postmenopausal bone loss. After withdrawal of alendronate (20 mg), bone loss resumed at the normal early postmenopausal rate.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015502 Absorptiometry, Photon A noninvasive method for assessing BODY COMPOSITION. It is based on the differential absorption of X-RAYS (or GAMMA RAYS) by different tissues such as bone, fat and other soft tissues. The source of (X-ray or gamma-ray) photon beam is generated either from radioisotopes such as GADOLINIUM 153, IODINE 125, or Americanium 241 which emit GAMMA RAYS in the appropriate range; or from an X-ray tube which produces X-RAYS in the desired range. It is primarily used for quantitating BONE MINERAL CONTENT, especially for the diagnosis of OSTEOPOROSIS, and also in measuring BONE MINERALIZATION. Absorptiometry, X-Ray,Dual-Photon Absorptiometry,Photodensitometry, X-Ray,Photon Absorptiometry,Single-Photon Absorptiometry,X-Ray Absorptiometry,Absorptiometry, Dual X-Ray,Absorptiometry, Dual-Energy Radiographic,Absorptiometry, Dual-Energy X-Ray,DEXA Scan,DPX Absorptiometry,DXA Scan,Densitometry, X-Ray,Densitometry, Xray,Dual X-Ray Absorptiometry,Dual-Energy Radiographic Absorptiometry,Dual-Energy X-Ray Absorptiometry,Dual-Energy X-Ray Absorptiometry Scan,Radiographic Absorptiometry, Dual-Energy,X-Ray Absorptiometry, Dual-Energy,X-Ray Photodensitometry,Absorptiometries, DPX,Absorptiometry, DPX,Absorptiometry, Dual Energy Radiographic,Absorptiometry, Dual Energy X Ray,Absorptiometry, Dual X Ray,Absorptiometry, Dual-Photon,Absorptiometry, Single-Photon,Absorptiometry, X Ray,DEXA Scans,DXA Scans,Densitometry, X Ray,Dual Energy Radiographic Absorptiometry,Dual Energy X Ray Absorptiometry,Dual Energy X Ray Absorptiometry Scan,Dual Photon Absorptiometry,Dual X Ray Absorptiometry,Photodensitometry, X Ray,Radiographic Absorptiometry, Dual Energy,Scan, DEXA,Scan, DXA,Scans, DEXA,Scans, DXA,Single Photon Absorptiometry,X Ray Absorptiometry,X Ray Absorptiometry, Dual Energy,X Ray Photodensitometry,X-Ray Absorptiometry, Dual,X-Ray Densitometry,Xray Densitometry
D015519 Bone Density The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS. Bone Mineral Content,Bone Mineral Density,Bone Densities,Bone Mineral Contents,Bone Mineral Densities,Density, Bone,Density, Bone Mineral

Related Publications

P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
March 1999, Bone,
P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
[Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
September 2002, Zhonghua yi xue za zhi,
P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.
January 2015, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,
P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.
February 1998, Annals of internal medicine,
P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
Effects of Alendronate on bone mass in women with osteoporosis.
January 2006, Medicinski pregled,
P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal.
September 2003, Bone,
P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
June 2003, The Keio journal of medicine,
P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women.
January 1993, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,
P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis.
June 2009, Therapeutics and clinical risk management,
P Ravn, and S R Weiss, and J A Rodriguez-Portales, and M R McClung, and R D Wasnich, and N L Gilchrist, and P Sambrook, and I Fogelman, and D Krupa, and A J Yates, and A Daifotis, and G E Fuleihan
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
February 2000, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!